‘Durvalumab’ can improve life span of lung cancer patients
The drug, ‘durvalumab’, can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years.
It has...
NICE recommends Tepotinib for advanced lung cancer
'Tepotinib’ has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell...